120 related articles for article (PubMed ID: 20200604)
1. Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics.
Dionisio D; Racalbuto V; Messeri D
Open AIDS J; 2010 Jan; 4():70-5. PubMed ID: 20200604
[TBL] [Abstract][Full Text] [Related]
2. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
[TBL] [Abstract][Full Text] [Related]
3. Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.
Satyanarayana K; Srivastava S
Open AIDS J; 2010 Jan; 4():41-53. PubMed ID: 20148091
[TBL] [Abstract][Full Text] [Related]
4. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
[TBL] [Abstract][Full Text] [Related]
5. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
Beall RF; Attaran A
Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
[TBL] [Abstract][Full Text] [Related]
6. Impending flop for brand antiretrovirals in the emerging markets?
Daniele D; Daniela M
Open AIDS J; 2008; 2():68-71. PubMed ID: 18923694
[TBL] [Abstract][Full Text] [Related]
7. Implications of patent pools on innovation regarding antiretrovirals.
Noehrenberg E
Open AIDS J; 2010 Jan; 4():67-9. PubMed ID: 20200606
[TBL] [Abstract][Full Text] [Related]
8. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?
Chien CV
PLoS One; 2007 Mar; 2(3):e278. PubMed ID: 17372625
[TBL] [Abstract][Full Text] [Related]
9. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
10. The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good.
Bermudez J; 't Hoen E
Open AIDS J; 2010 Jan; 4():37-40. PubMed ID: 20309404
[TBL] [Abstract][Full Text] [Related]
11. Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health.
Beck EJ; Passarelli C; Lui I; Guichard AC; Simao M; De Lay P; Loures L
Antivir Ther; 2014; 19 Suppl 3():117-23. PubMed ID: 25310477
[TBL] [Abstract][Full Text] [Related]
12. Technology Development Through Pooling ARV Drug Patents: A Vision from China.
Liu L; Lu H
Open AIDS J; 2010 Jan; 4():54-9. PubMed ID: 20224635
[TBL] [Abstract][Full Text] [Related]
13. Intellectual property rights, market competition and access to affordable antiretrovirals.
Pascual F
Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
[TBL] [Abstract][Full Text] [Related]
14. Past, present and future of pharmaceutical patents under Korea-US Trade Agreement.
Shin YS
Pharm Pat Anal; 2016 Jul; 5(4):237-48. PubMed ID: 27338849
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
16. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
Babovic S; Wasan KM
J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
[TBL] [Abstract][Full Text] [Related]
17. Designing equitable antiretroviral allocation strategies in resource-constrained countries.
Wilson DP; Blower SM
PLoS Med; 2005 Feb; 2(2):e50. PubMed ID: 15737005
[TBL] [Abstract][Full Text] [Related]
18. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
Crager SE; Guillen E; Price M
Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
[TBL] [Abstract][Full Text] [Related]
19. Enforcement costs: some humanitarian alternatives to stronger patent rights.
Trotter A
Med Leg J; 2012; 80(Pt 1):22-32. PubMed ID: 22403122
[TBL] [Abstract][Full Text] [Related]
20. How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
Beall RF; Hardcastle L; Clement F; Hollis A
Health Policy; 2019 Dec; 123(12):1251-1258. PubMed ID: 31601457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
